Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.

Authors :: El Ahmar, Nourhan
Matar, Sayed
Jegede, Opeyemi
Savla, Varunika
Bagheri Sheshdeh, Aseman
Ghandour, Fatme
Denize, Thomas
West, Destiny
Choueiri, Toni K.
Catalano, Paul J.
Braun, David A.
Haas, Naomi B.
Hammers, Hans J.
Bilen, Mehmet Asim
Stein, Mark N.
Sosman, Jeffrey A.
Wu, Catherine J.
McDermott, David F.
Atkins, Michael B.
Signoretti, Sabina
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4549-4549, 1p
Publication Year :: 2023

Full Text Access

Tools